EUROPEAN JOURNAL OF EMERGING MEDICINE AND PUBLIC HEALTH

THE GREAT MIMICKER: WHY A THOUGHTFUL APPROACH TO CYTOMEGALOVIRUS IS CRUCIAL

Author Details:

Dr. Leona R. Veltric
Department of Infectious Diseases, Royal College of Surgeons in Ireland, Dublin, Ireland

Dr. Sandeep K. Maretla
Division of Clinical Microbiology, Christian Medical College, Vellore, India

Dr. Carla D. Inveren
Department of Medical Sciences, University of Padua, Italy

V0LUME01 ISSUE01 (2024)
Published Date: 23 December 2024 // Page no.: - 50-54

ABSTRACT

In the vast world of infectious diseases, few pathogens are as enigmatic as Cytomegalovirus (CMV). This ubiquitous betaherpesvirus is a master of disguise, capable of causing a dizzying array of clinical pictures. In most healthy people, it passes like a silent ghost, leaving no trace of its visit. But for those with developing or weakened immune systems—newborns and transplant patients, for example—CMV can be a devastating force, causing severe, disseminated, and life-threatening illness. Congenital CMV (cCMV) is the most common infection passed from mother to child before birth and a primary non-genetic reason for permanent hearing loss and long-term neurodevelopmental challenges. The true challenge of CMV lies in its ability to mimic a multitude of other conditions. Its symptoms frequently overlap with other infections, as well as genetic, metabolic, and systemic disorders, making it a true "great mimicker" in clinical medicine. This diagnostic puzzle demands a careful and comprehensive approach from any physician. Getting the diagnosis right is everything; it shapes treatment, guides conversations with families, and sets the course for a patient's entire life. This review walks through the story of CMV—from its complex biology to the diverse ways it presents in our patients—and makes the case for why a thoughtful differential diagnosis is critical to unmasking the true culprit when CMV is found at the scene.

Keywords: Cytomegalovirus, CMV, congenital CMV, differential diagnosis, TORCH infections, immunocompromised host, sensorineural hearing loss, neurodevelopmental outcome, virological testing, ganciclovir, valganciclovir.

INTRODUCTION

The Two Faces of an Ancient Virus

Human Cytomegalovirus (HCMV) has been our silent companion for millennia. As a member of the herpesvirus family, it has perfected the art of co-existence. So much so that a majority of the world's population—anywhere from 40% to 100%, depending on the region—carries the virus [3, 4]. After its initial entry, CMV doesn't leave. It retreats into our cells, establishing a lifelong, quiet presence in our myeloid progenitors, ready to re-emerge if the conditions are right [3].

The story of a CMV infection is a tale of two very different hosts. For the vast majority of us with robust immune systems, our first encounter with CMV is utterly unremarkable. More than 90% of the time, it's completely asymptomatic, or at worst, it causes a vague, flu-like illness that's easily forgotten [14]. But for two specific groups—the developing fetus and the immunocompromised individual—CMV is not a quiet companion. It's a formidable threat.

Congenital CMV is a story that unfolds in the womb, when the virus crosses the placenta from mother to child. It's a far more common event than most people realize, affecting up to 1 in 40 live births, making it the most frequent congenital infection we see [2, 4]. For these babies, the consequences can be life-altering. While most appear healthy at birth, they carry a hidden risk for future problems, especially progressive hearing loss that can emerge months or even years later [5, 8]. For the 10-15% of infants who are clearly sick at birth, the outlook can be grim. They face a daunting list of potential challenges: cerebral palsy, cognitive delays, vision loss, and seizures, all on top of a high risk for profound hearing loss [1, 13].

Herein lies the clinician's dilemma. The warning signs of cCMV in a newborn—a small body size, an enlarged liver and spleen, jaundice, a low platelet count—are not unique calling cards. They are a generic distress signal sent by a sick

baby, a signal that could just as easily point to other congenital infections like toxoplasmosis or rubella, a serious bacterial infection, or even a hidden genetic or metabolic disorder [4, 11]. This clinical fog makes a swift and certain diagnosis incredibly difficult, yet it's exactly what's needed to start potentially sight- and hearing-saving treatment and to have honest conversations with worried families [9, 13].

This article was born from the kind of clinical cases that stick with you—the ones where CMV was present, but it wasn't the whole story. It's a deep dive into this complex virus, exploring not just what it is, but what it *does* to people, and how we can learn to look past the obvious to find the complete truth.

2. A Master of Deception: How CMV Works

CMV is the largest of the human herpesviruses, and it uses its size to its advantage, carrying a vast toolkit of over 165 proteins in its genetic code. This isn't just for show; this is the arsenal it uses to wage a sophisticated campaign of immune evasion [3]. When the virus enters the body, it doesn't just infect one type of cell; it's a generalist, making a home in epithelial cells, endothelial cells, and more. In a tissue sample, its calling card is the "cytomegalic cell"—an infected cell that has become swollen and bloated, with a large, dark inclusion in its nucleus that pathologists famously describe as an "owl's eye" [7].

The true genius of CMV is its ability to hide. It establishes a latent, or dormant, state primarily within the very cells that are supposed to give rise to our immune defenders [3]. While it's hiding, it's silent, expressing almost no viral genes, making it invisible to the immune system's patrols. It waits patiently for a trigger—a signal of inflammation, or the profound immune suppression that comes with an organ transplant—to awaken and reactivate.

To survive, CMV has evolved an incredible array of tricks to outsmart our immune system. It can pull MHC molecules—the signposts our cells use to show they're infected—off the cell surface, effectively putting on an invisibility cloak to hide from our best virus-killing T cells. It produces proteins that act like decoys to confuse Natural Killer cells and even manufactures its own version of an immunosuppressive chemical, Interleukin-10, to calm the local immune response [3, 7]. This mastery of deception is how it guarantees its own survival for the entire life of its host.

In a developing fetus, the damage comes from a one-two punch: the virus directly kills developing cells, and the body's own inflammatory response to the invader causes collateral damage. In the brain, this can disrupt the intricate process of development, leading to permanent structural problems, while in the delicate structures of the inner ear, it leads to hearing loss.

3. The Many Faces of CMV

How a CMV infection looks depends entirely on who the patient is.

3.1 The Newborn: A Spectrum of Possibility

The Sick Newborn (Symptomatic cCMV): About one in ten infected babies are born with obvious signs of illness, which can be severe and involve multiple organ systems [1, 5].

- **The Brain:** A small head (microcephaly), enlarged brain ventricles, tell-tale calcifications seen on an ultrasound, seizures, or floppy/stiff muscle tone.
- **The Liver:** An enlarged liver and spleen, jaundice that persists, and abnormal liver function tests.
- **The Blood:** A low platelet count, which can cause tiny red spots (petechiae) or a classic "blueberry muffin" rash from the body trying to make blood cells outside the bone marrow.
- **The Senses:** Inflammation of the retina (chorioretinitis) and, most critically, hearing loss that is already present at birth.
- **Growth:** A baby who is significantly smaller than expected for their gestational age.

The Seemingly Healthy Newborn (Asymptomatic cCMV): The vast majority of babies with cCMV look perfectly healthy at birth [5]. But the virus can be a ticking time bomb. Of these children, up to 15% will develop problems later on, most commonly hearing loss that can appear suddenly or worsen over time [8].

The Long Road Ahead: The lasting legacy of cCMV is primarily neurological. Hearing loss is the most common single problem, and it's a major target for early detection because hearing aids or cochlear implants can make a world of difference. Other potential long-term challenges include cerebral palsy, intellectual disability, vision problems, and epilepsy [2, 13].

3.2 The Patient with a Weakened Immune System

For someone whose immune system is suppressed, CMV is a constant threat. It's often not a new infection, but the reawakening of the latent virus that has been dormant for years.

- **Transplant Patients:** After an organ transplant, CMV is a major cause of illness and even death. It can show up as a fever and flu-like illness, or it can invade organs directly, causing a life-threatening pneumonia, hepatitis, or severe gastrointestinal disease [7].
- **Patients with HIV/AIDS:** In the era before effective antiviral drugs, CMV retinitis was a feared complication that often led to blindness.

3.3 The Healthy Child or Adult

In a healthy person, a first-time CMV infection is usually a non-event. If it does cause symptoms, it's typically a **mononucleosis-like syndrome** with a persistent fever, fatigue, and muscle aches [4]. Unlike the classic "mono"

caused by EBV, a sore throat is usually not a major feature. It's exceptionally rare for CMV to cause serious problems in healthy people, but cases of colitis, hepatitis, and neurological issues have been reported [6, 7].

4. The Clinician's Toolkit: Unraveling the Diagnosis

Solving a CMV mystery requires a thoughtful selection of tests, because each one tells a different part of the story.

4.1 Finding the Virus Itself

The most direct way to diagnose an active infection is to find the virus's genetic material.

- **Polymerase Chain Reaction (PCR):** This is the workhorse of modern CMV diagnostics.
    - **For Newborns:** The "gold standard" for diagnosing cCMV is a positive PCR test on a baby's urine or saliva collected **within the first three weeks of life** [1, 5]. This timing is critical. A positive test after three weeks could mean the baby was infected during or after birth, which carries a much different prognosis.
    - **For Everyone Else:** A quantitative PCR test on blood, which measures the "viral load," is essential for managing CMV in transplant patients. A rising viral load is a red flag for impending disease [10]. PCR can also be run on spinal fluid, lung fluid, or tissue samples to pinpoint an infection in a specific organ [12].
- **Viral Culture:** This is the old-school method of growing the virus in a lab. It works, but it's slow and less sensitive than PCR, so it's rarely used today [11].

4.2 Reading the Immune Response

Serology looks for the antibodies our bodies make in response to the virus. It's great for telling if someone has had CMV in the past, but it can be a trap for diagnosing active disease.

- **IgG Antibodies:** A positive CMV IgG simply means "you've met this virus before." It's useful for screening organ donors and recipients, but in a newborn, it's useless for diagnosis because the baby inherits all of the mother's IgG antibodies [1, 4].
- **IgM Antibodies:** A positive IgM is often thought to mean "new infection," but with CMV, it's not that simple. IgM can pop up during reactivation of an old infection and can stay positive for months, making it an unreliable marker of a recent, primary infection [3, 10].
- **IgG Avidity:** This is a more sophisticated test that can help. It measures how tightly the IgG antibodies are binding to the virus. A weak, or "low-avidity," bond suggests the immune response is new—a primary infection within the last few months. A strong, "high-avidity," bond indicates a more mature response from an infection in the distant past. This can be very helpful for a pregnant woman who tests positive for CMV, as it can help determine her risk of transmitting the virus to her baby [1, 8].

4.3 Looking at the Pictures

- **Cranial Ultrasound:** This is a key first step in evaluating a baby with suspected cCMV. It can show the classic periventricular calcifications or enlarged ventricles [5]. It might also show **lenticulostriate vasculopathy**—bright-looking blood vessels in a deep part of the brain. While this finding is associated with cCMV, it's not specific and can be seen in other conditions or even in healthy babies, so it must be interpreted with caution [15, 16].
- **Magnetic Resonance Imaging (MRI):** An MRI gives a much more detailed picture of the brain's structure and is better at finding subtle but important abnormalities that can help predict a child's long-term neurodevelopmental outcome [1, 11].

4.4 Under the Microscope

When CMV is suspected of invading an organ like the gut or liver, a biopsy is the only way to be sure. The pathologist looks for the tell-tale "owl's eye" inclusions in the tissue, which confirms a diagnosis of tissue-invasive disease [7].

5. The Art of Medicine: Looking Beyond the Obvious

The central challenge of CMV is not in running the tests, but in interpreting the results. A positive CMV test can feel like an answer, but sometimes, it's just a distraction. The clinical stories of infants who had positive CMV tests but whose real problems were a congenital heart defect or cystic fibrosis are powerful cautionary tales [Stopyra et al., 2024].

5.1 The Newborn Puzzle: cCMV or Something Else?

When a newborn is sick with jaundice, an enlarged liver, and a low platelet count, the list of possibilities is long and intimidating.

- **The Usual Suspects (TORCH):** Is it Toxoplasmosis, Rubella, Herpes, or another congenital infection?
- **A Systemic Infection:** Could this be bacterial sepsis?
- **A Problem with Metabolism:** Could it be a rare genetic disorder like galactosemia?
- **A Deeper Structural Problem:** As we've seen, a failing heart can cause poor brain perfusion, leading to imaging findings that mimic cCMV [15, 16]. The malabsorption and liver problems of cystic fibrosis can also look remarkably like a systemic viral infection.

The lesson is clear: even if a baby's CMV test comes back positive, if the clinical picture doesn't quite fit—if there are unusual facial features, a distinct heart murmur, or symptoms that aren't classic for CMV—the search isn't over. The art of medicine is knowing when to keep looking.

5.2 Thinking Through the Case

- **Case 1 (The Heart's Deception):** Imagine a 4-month-old who isn't growing well and seems delayed. An ultrasound shows lenticulostriate vasculopathy, and a urine CMV PCR is positive. It's easy to label this cCMV and stop. But a careful doctor listens to the chest and hears a loud murmur. An echocardiogram confirms a large hole in the heart, causing heart failure. After surgery, the baby thrives. The CMV was just a bystander.
- **Case 2 (The Gut's Secret):** A 3-month-old has unrelenting diarrhea, isn't gaining weight, and has swollen legs from low protein. The labs show liver inflammation, and CMV tests are positive. It looks like a classic case of CMV enteritis. But the symptoms persist. A smart clinician remembers the other causes of malabsorption and orders a sweat test. It comes back sky-high, revealing the true diagnosis: cystic fibrosis.

5.3 To Treat or Not to Treat?

The decision to use antiviral medication is highly specific.

- **For Congenital CMV:** A six-month course of the oral antiviral drug valganciclovir is now the standard of care for newborns with symptomatic cCMV that affects their brain [1, 13]. Studies have shown this can improve long-term hearing and developmental outcomes [1, 9]. For babies who are asymptomatic, treatment is not currently recommended.
- **For Immunocompromised Patients:** Antiviral therapy is a cornerstone of management, used both to treat active disease and, in many high-risk transplant patients, to prevent it from ever occurring.

5.4 The Horizon: Screening and Prevention

The heavy burden of cCMV has sparked a passionate debate about screening all newborns at birth [8]. It would allow us to find every child with hearing loss early and get them the help they need. But it also raises difficult questions about cost, parental anxiety, and what to do for the thousands of asymptomatic babies who would be identified.

For now, prevention focuses on simple, practical advice for pregnant women: wash your hands frequently, especially after changing diapers or wiping a young child's nose, as this can reduce the risk of acquiring the virus during pregnancy. The ultimate goal, the holy grail of CMV research, is a vaccine that could protect future generations from this ancient virus [2].

CONCLUSION

A Call for Clinical Wisdom

Cytomegalovirus is more than just a pathogen; it's a lesson in clinical humility. It teaches us that things are not always as they seem. Its ability to cause devastating disease in one patient while lying dormant in another makes it a diagnostic tightrope walk. A positive test, especially one found weeks or months after birth, must be viewed with a healthy dose of skepticism. It could be the villain of the story, a minor accomplice, or simply an innocent bystander. The powerful stories of children whose lives were changed not by treating their CMV, but by finding the underlying heart defect or genetic condition, are a stark reminder that our job is to see the whole patient. The identification of CMV should never be the end of the diagnostic journey. Rather, it should be one clue in a complex puzzle, one that requires our full attention, our curiosity, and our clinical wisdom to solve correctly for the sake of the patient in front of us.

REFERENCES

1. Luck SE, Wieringa JW, Blázquez-Gamero D, Henneke P, Schuster K, Butler K, Capretti MG, Cilleruelo MJ, Curtis N, Garofoli F, et al. Congenital Cytomegalovirus: A European Expert Consensus Statement on Diagnosis and Management. Pediatr Infect Dis J. 2017;36(12):1205–1213.
2. Kabani N, Ross SA. Congenital Cytomegalovirus Infection. J Infect Dis. 2020;221(Suppl 1):S9–S14.
3. Schottstedt V, Blümel J, Burger R, et. al. Human Cytomegalovirus (HCMV) – Revised. Transfus Med Hemother. 2010;37(6):365–375.
4. Cytomegalovirus Infection. In: Kimberlin DW, Brady MT, Jackson MA, Long SS (eds.). Red Book: 2015 Report of the Committee on Infectious Diseases. 29th ed. American Academy of Pediatrics. Elk Grove Village, IL, 2015: 317–322.
5. Gantt S, Bitnun A, Renaud C, Kakkar F, Vaudry W. Diagnosis and management of infants with congenital cytomegalovirus infection. Paediatr Child Health. 2017;22(2):72–74.
6. Sue PK, Salazar-Austin NM, McDonald OG, et al. Cytomegalovirus Enterocolitis in Immunocompetent Young Children: A Report of Two Cases and Review of the Literature. Pediatr Infect Dis J. 2016;35(5):573–576.
7. Nakase H, Herfarth H. Cytomegalovirus Colitis, Cytomegalovirus Hepatitis and Systemic Cytomegalovirus Infection: Common Features and Differences. Inflamm Intest Dis. 2016;1(1):15–23.
8. Lazzarotto T, Blázquez-Gamero D, Delforge M-L, et al. Congenital Cytomegalovirus Infection: A Narrative Review of the Issues in Screening and Management From a Panel of European Experts. Front Pediatr. 2020;8:13.
9. Fischler B, Casswall TH, Malmborg P, Nemeth A. Ganciclovir treatment in infants with cytomegalovirus infection and cholestasis. J Pediatr Gastroenterol Nutr.

2002;34(2):154–157.

10. Akhter K. Cytomegalovirus (CMV) Workup. Medscape. Accessed June 21, 2024, https://emedicine.medscape.com/article/215702-workup?form=fpf
11. Schleiss MR. Pediatric Cytomegalovirus Infection Workup. Medscape. Accessed June 21, 2024, https://emedicine.medscape.com/article/963090-workup?form=fpf
12. Pokorska-Śpiewak M, Niezgoda A, Gołkowska M, et al. Recommendations for the diagnosis and treatment of CMV infections. Polish Society of Epidemiology and Infectious Diseases. Przegl Epidemiol. 2016;70(2):297–310.
13. Khalil A, Heath P, Jones C, Soe A, Ville YG on behalf of the Royal College of Obstetriciansand Gynaecologists. Congenital Cytomegalovirus Infection: Update on Treatment. Scientific Impact Paper No. 56. BJOG. 2018;125:e1–e11, https://doi.org/10.1111/1471-0528.14836.
14. Flisiak R (red.). Choroby zakaźne i pasożytnicze. Cytomegalia. Wyd. I. Lublin: Czelej, 2020:751–756.
15. Makhoul IR, Eisenstein I, Sujov P, Soudack M, Smolkin T, Tamir A, Epelman M. Neonatal lenticulostriate vasculopathy: further characterisation. Arch Dis Child Fetal Neonatal Ed. 2003;88(5):F410-4, https://doi.org/10.1136/fn.88.5.f410.
16. Wang HS, Kuo MF, Chang TC. Sonographic lenticulostriate vasculopathy in infants: some associations and a hypothesis. AJNR Am J Neuroradiol. 1995;16(1):97–102.